EDC 1
Alternative Names: EDC-1Latest Information Update: 12 Sep 2023
At a glance
- Originator Wisconsin Alumni Research Foundation
- Developer Centrose
- Class Antineoplastics; Cardiac glycosides; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pancreatic cancer
- No development reported Lymphoma; Renal cancer
Most Recent Events
- 12 Sep 2023 EDC 1 is still in preclinical trials for Pancreatic cancer in USA (Transdermal) (Centrose Pharma pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Renal-cancer in USA (Transdermal, Patch)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Lymphoma in USA (Transdermal, Patch)